Blood Viscometer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The blood viscometer market size was valued at USD 1.74 billion in 2025 and is estimated to grow from USD 1.84 billion in 2026 to reach USD 2.44 billion by 2031, at a CAGR of 5.83% during the forecast period (2026-2031). This report is segmented by Product Type (Rotational Viscometers, Capillary Viscometers, and More), Application (Clinical Diagnostics and Patient Monitoring, Hematology and Blood Research, and More), End User (Hospitals and Diagnostic Laboratories, Research and Academic Institutes, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Blood Viscometer Market Trends and Insights

Rising Cardiovascular and Metabolic Disease Burden

The blood viscometer market is gaining support from the connection between elevated blood viscosity and cardiovascular disease. Higher hematocrit, fibrinogen, and reduced red blood cell deformability can increase shear resistance and thrombotic risk in coronary and cerebrovascular circulation. A 2024 projection using Global Burden of Disease 2019 data estimated 20.5 million cardiovascular deaths in 2025 and 35.6 million deaths in 2050, while high systolic blood pressure accounted for 18.9 million future cardiovascular deaths. A 2024 study also linked elevated whole-blood viscosity with impaired insulin-stimulated myocardial glucose metabolism, connecting blood rheology to metabolic and cardiac comorbidity. A 2025 European Society of Cardiology cohort found that whole-blood viscosity differed across ischemic heart disease subtypes and correlated with clinical and laboratory measures. This evidence allows the blood viscometer market to address cardiology, neurology, and diabetes care, rather than remain limited to hematology, where viscosity testing has historically been most familiar.

Growing Hematological and Hyperviscosity Disorders

Hyperviscosity syndrome occurs across polycythemia vera, Waldenström macroglobulinemia, sickle cell disease, plasma cell disorders, and autoimmune conditions. These conditions can require viscosity monitoring when clinicians consider plasmapheresis, phlebotomy, or cytoreductive treatment. A 2025 longitudinal study of 63 patients with sickle cell anemia found that steady-state blood viscosity was the only factor independently associated with vaso-occlusive crisis rates in its multivariate model. A 2025 American Society of Hematology abstract described protocols for measuring whole-blood viscosity under hypoxic conditions, which is important to sickle cell disease monitoring. Specialty hematology centers may use these instruments at several points during care, which supports repeat testing and recurring calibration or consumable demand. Drug developers working on hydroxyurea alternatives and gene therapies can also use viscometry as an outcome measure in clinical programs, creating demand alongside routine specialty-care testing.

High Instrument, Calibration, and Maintenance Costs

The blood viscometer market faces a cost barrier because the purchase price is only part of the total ownership. Service contracts, calibration kits, operator training, and quality-control materials add continuing expense for hospitals. An AABB review notes that institutions considering viscoelastic testing need to assess cost-effectiveness against both clinical outcomes and the higher capital and operating costs involved. Clinical-grade high-shear testing also requires temperature control, precise calibration, and regular quality checks. These requirements contribute to a split between premium automated systems in well-equipped hospitals and lower-cost systems used in price-sensitive procurement. The shortage of trained operators and local application support further limits adoption in parts of Asia-Pacific, the Middle East, Africa, and South America, where service coverage can be limited outside major urban centers.

Other drivers and restraints analyzed in the detailed report include:

• Automated and Digital Laboratory Workflows
• Point-of-Care and Decentralized Diagnostics
• Limited Clinical Standardization and Reimbursement

Segment Analysis

Rotational viscometers held 38.94% of revenue in 2025, which reflected established clinical use and broad shear-rate coverage from 0.1 to 1,000 s⁻¹. These systems can assess whole-blood and plasma samples under temperature-controlled conditions. Hospitals in the blood viscometer market often favor familiar systems because their staff understands the workflow and quality procedures. Quality management requirements under ISO 13485 reinforce demand for suppliers that can document manufacturing controls and post-market surveillance. This makes it harder for new vendors to replace established rotational platforms in hospital contracts.

Capillary viscometers are forecast to grow at a 6.24% CAGR from 2026 to 2031. This growth reflects their expanding use in stroke research and in smaller laboratory settings. Publications in 2024 and 2025 used scanning capillary-tube systems to examine blood viscosity in acute ischemic stroke and white-matter hyperintensity cohorts. Automated capillary platforms in the blood viscometer market can reduce footprint and lower operator requirements. A February 2026 evaluation found that a curved-capillary U-tube configuration produced results close to straight-capillary benchmarks. Microfluidic systems also serve low-volume pediatric, rare-disease, and pharmaceutical screening use cases, as RheoSense states that its m-VROC II uses samples as small as 15 μL.

Complete Report Scope:

• By Product Type
  • Rotational Viscometers
  • Capillary Viscometers
  • Microfluidic Viscometers
  • Others
• By Application
  • Clinical Diagnostics and Patient Monitoring
  • Hematology and Blood Research
  • Point-of-Care Testing
  • Pharmaceutical and Biotechnology Applications
  • Others
• By End User
  • Hospitals and Diagnostic Laboratories
  • Research and Academic Institutes
  • Pharmaceutical and Biotechnology Companies
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 35.73% of revenue in 2025, which made it the largest regional blood viscometer market. The region has a large cardiovascular patient population, high healthcare spending, and many academic medical centers. These centers act as users and development partners for manufacturers. Major U.S. hospital systems can standardize platforms across several sites, supporting recurring service and consumables demand. This structure creates switching barriers for incumbent vendors.

Europe was the second-largest regional blood viscometer market, with Germany, the United Kingdom, and France as key country markets. Universal healthcare systems, older populations, and established clinical hematology practices support routine use of plasma-viscosity testing. ISO 13485 requirements also direct procurement toward suppliers with documented quality systems. Asia-Pacific is forecast to grow at an 8.27% CAGR from 2026 to 2031, the fastest regional rate. China, India, South Korea, and Japan are expanding hospital capacity and diagnostic infrastructure. Chinese public hospital programs and domestic instruments, including systems from Beijing Steellex Scientific Instrument Co., Ltd., support adoption in county and tertiary hospitals.

National stroke-care programs in China are modernizing blood-rheology testing and widening the demand base beyond individual clinical users. Private multispecialty hospital chains in India have incorporated viscometry into nephrology and oncology care pathways. South Korea and Japan are integrating viscosity data with AI-assisted diagnostic dashboards and robotic hemostasis analyzers. The Middle East and Africa are smaller markets, but laboratory automation investment in Saudi Arabia and the UAE is increasing demand at tertiary hospitals. South Africa remains the most developed sub-Saharan diagnostic market, although premium use is limited to select centers. Brazil and Argentina lead South American demand, where public hospitals are beginning to add hemorheological testing to stroke and hematology workflows. Lower-cost point-of-care and microfluidic formats could help the blood viscometer market gain ground in these price-sensitive regions as production volumes increase.

List of Companies Covered in this Report:

• A&D Company, Limited
• AMETEK Brookfield
• Anton Paar
• ATAGO Co., Ltd.
• Beijing Steellex Scientific Instrument Co., Ltd.
• Benson Viscometers Ltd.
• BioFluid Technology, Inc.
• Canon
• CSC Scientific Company, Inc.
• Fann Instrument Company
• Health Onvector, Inc.
• Labtron Equipment
• LAMY RHEOLOGY
• LAUDA Scientific GmbH
• Microvisk Technologies Ltd.
• PCE Instruments
• proRheo GmbH
• Rheonics GmbH
• RheoSense, Inc.
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support